Skip to content

Trial · Observational

RecruitingPhase not statedRegistry data

DDAVP Effect by TEG6 in Cardiac Surgery

NCTNCT07179991 (opens ClinicalTrials.gov in a new tab)Other idDDAVP TEG6
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Recruiting
Phase
Phase not stated
Enrollment
100 participants (estimated)
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Other
Design
Not stated
Countries
1 country

Canada

Start
1 Aug 2026
Primary completion
1 Dec 2028 (estimated)
Completion
31 Dec 2028 (estimated)
First posted
18 Sept 2025
Last update posted
21 Sept 2026
Conditions
Intraoperative Bleeding

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2026202720282029
  1. Ph –

    DDAVP Effect by TEG6 in Cardiac Surgery

    NCT07179991

    1 Aug 2026 to est. 31 Dec 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Cardiopulmonary bypass (CPB) is a process that uses a pump that temporarily takes over the function of the heart and lungs during cardiac surgery to maintain blood circulation and oxygenation. Using CPB during cardiac surgery can result in complications with blood clotting. Blood clotting is achieved when molecules in the blood, called platelets, are able to form together with the help of other clotting factors to form a clot. A drug called desmopressin (DDAVP) is used to help blood clot properly by increasing the amount of clotting factors in the blood. Several studies have shown that desmopressin has the ability to reduce the amount of blood transfusions needed for cardiac surgery patients in the postoperative period. At LHSC desmopressin is frequently requested by Cardiac Surgeons and Anesthesiologists to stop bleeding and promote blood clotting where required. A test called TEG6s platelet mapping is a blood test used to help manage the use of blood products by being able to provide information on platelet function and blood clotting activity. At the moment, there is a lack of information regarding the use of TEG6s platelet mapping to analyze the effect of desmopressin on blood clotting in cardiac surgery patients after CPB. The purpose of this study is to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery with CPB. By using TEG6s platelet mapping, this study aims to observe dynamic changes in platelet function following desmopressin administration at various time points in the perioperative and postoperative periods.

Interventions

  • Desmopressin after protamine reversalDrug

Arms1

  • Other

    Desmopressin after protamine reversal

    Desmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB).

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in platelet function due to desmopressin administration after cardiopulmonary bypass

    Time frame · After arterial line insertion - 24 hours after admission to the intensive care unit

    Registry description

    This will be measured by TEG6s platelet mapping.

Secondary outcomes(2)

  1. Impact of desmopressin on transfusion products required

    Time frame · After arterial line insertion - 24 hours after admission to the intensive care unit

    Registry description

    This will be measured by recording the amount of blood products required for transfusion.

  2. Impact of desmopressin on chest drainage

    Time frame · After arterial line insertion - 24 hours after admission to the intensive care unit

    Registry description

    This will be measured by recording the fluid drained from the chest of participants

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies6

Studies that cite this trial.

Studies with results

2 studies on this page

Indexing hint: Randomized controlled trial · 1999

8 results

Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial.

Despotis et al. 1999Lancet (London, England)cited by 76

PMID 10408485DOI 10.1016/s0140-6736(98)12494-7PUB-10408485

Full text at the publisher8 results
Publisher pageSee results (8)

Indexing hint: Randomized controlled trial · 1992

2 results

The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification.

Mongan et al. 1992Anesthesiologycited by 83

PMID 1610009DOI 10.1097/00000542-199207000-00007PUB-01610009

Rights unknown2 results
Source linkSee results (2)

More studies

4 studies on this page

Indexing hint: Randomized controlled trial · 2015

Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery.

Jin et al. 2015Chinese medical journalcited by 14

PMID 25698197PMC4834776DOI 10.4103/0366-6999.151663PUB-25698197

Free to read · publisher termsCC BY-NC
Read at source

Indexing hint: Randomized controlled trial · 2001

Desmopressin usage in elective cardiac surgery.

Ozkisacik et al. 2001The Journal of cardiovascular surgerycited by 10

PMID 11698939PUB-11698939

Full text at the publisher
Publisher page

Indexing hint: Meta-analysis (pooled) · 1995

The effect of desmopressin on reducing blood loss in cardiac surgery--a meta-analysis of double-blind, placebo-controlled trials.

Cattaneo et al. 1995Thrombosis and haemostasiscited by 51

PMID 8560415DOI 10.1055/s-0038-1649883PUB-08560415

Full text at the publisher
Publisher page

Indexing hint: Randomized controlled trial · 1991

Hemodynamic responses to desmopressin acetate after CABG: a double-blind trial.

Salmenperä et al. 1991Journal of cardiothoracic and vascular anesthesiacited by 10

PMID 1863726DOI 10.1016/1053-0770(91)90328-qPUB-01863726

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: 1. Age 18 years and above 2. Undergoing elective cardiac surgery with cardiopulmonary bypass 3. Able to provide informed consent Exclusion Criteria: 1. Hyponatremia 2. Allergy to desmopressin or its components 3. History of coronary artery disease with thrombosis 4. Recent history of thromboembolic events (Stroke/TIA/DVTs) 5. Severe Renal Impairment Creatinine Clearance\<30 ml/min 6. Inability to communicate in the English language

PepBank is a research reference. Talk to a doctor before you use any peptide.